Tumor thrombus: incidence, imaging, prognosis and treatment
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Intravascular tumor extension, also known as tumor thrombus, can occur in many different types of cancer. Those with the highest proclivity include Wilm's tumor, renal cell carcinoma (RCC), adrenal cortical carcinoma (ACC) and hepatocellular carcinoma (HCC). The presence of tumor thrombus markedly worsens prognosis and impacts treatment approach. Imaging plays a key role in its diagnosis. Endovascular methods also play a large role in treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832 · cited 1×
“Survival of those treated with Sorafenib is improved by only a modest 2–3 months (75,76).”
BackgroundEASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
AASLD guidelines for the treatment of hepatocellular carcinoma
Heimbach, J. K., Kulik, L. M., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., Zhu, A. X., Murad, M. H., & Marrero, J. A. (2018) · Hepatology · doi:10.1002/hep.29086 · Cited by 4,070 · cited 2×
“According to the American Association for the Study of Liver disease (AASLD), the European Association for the Study of the Liver (EASL), and the BCLC treatment guidelines, it is the recommended treatment for BCLC stage C patients (72,73).”
MethodForner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017 · cited 1×
“Sorafenib is a multi-kinase inhibitor, targeting VEGFR, PDGFR and Raf family kinases (71).”
BackgroundMickisch, G., Garin, A., van Poppel, H., de Prijck, L., & Sylvester, R. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06103-7 · Cited by 1,410 · cited 1×
“In the presence of known metastatic disease, surgical tumor debulking not only improves symptoms but can also prolong survival, especially when targeted chemotherapy is subsequently employed (33-35).”
BackgroundCurrent Strategy for Staging and Treatment: The BCLC Update and Future Prospects
Forner, A., Reig, M. E., Rodriguez de Lope, C., & Bruix, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247133 · Cited by 1,110 · cited 1×
“HCC patients with any macroscopic vascular invasion are classified as Barcelona Clinic Liver Cancer (BCLC) stage C (advanced stage) (Table 5) (57-59).”
BackgroundEASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Salem, R., Lewandowski, R. J., Mulcahy, M. F., Riaz, A., Ryu, R. K., Ibrahim, S., Atassi, B., Baker, T., Gates, V., Miller, F. H., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.006 · Cited by 1,074 · cited 1×
“Se lec t ive in terna l rad io-embol iza t ion (SIRT) using Yittrium-90 (Y-90) is considered by many to be the preferred treatment of patients with HCC and portal vein tumor invasion (88,89).”
MethodOmata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026 · cited 1×
“The Asian Pacific Association for the Study of the Liver (APASL) guidelines recommend TACE in the setting of branch vessel thrombus in Child-Pugh A and B patients (86).”
BackgroundCytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined Analysis
FLANIGAN, R. C., MICKISCH, G., SYLVESTER, R., TANGEN, C., VAN POPPEL, H., & CRAWFORD, E. D. (2004) · Journal of Urology · doi:10.1097/01.ju.0000110610.61545.ae · Cited by 872 · cited 1×
“In the presence of known metastatic disease, surgical tumor debulking not only improves symptoms but can also prolong survival, especially when targeted chemotherapy is subsequently employed (33-35).”
BackgroundTakayasu, K., Arii, S., Ikai, I., Omata, M., Okita, K., Ichida, T., Matsuyama, Y., Nakanuma, Y., Kojiro, M., Makuuchi, M., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.05.021 · Cited by 810 · cited 1×
“The presence of PVTT has been shown to have a more significant effect on prognosis than tumor size (53).”
BackgroundDiffusion-weighted MR Imaging of the Liver
Taouli, B., & Koh, D.-M. (2010) · Radiology · doi:10.1148/radiol.09090021 · Cited by 810 · cited 1×
“Tumor thrombus has an increased cellular density and nuclear to cytoplasm ratios and will show restricted diffusion, appearing bright on diffusion weighted imaging (DWI) and dark on apparent diffusion coefficient (ADC) mapping (66).”
BackgroundBurroughs, A., Dufour, J.-F., Galle, P., Mazzaferro, V., Piscaglia, F., Raoul, J., Sangro, B., & Bolondi, L. (2013) · Seminars in Liver Disease · doi:10.1055/s-0032-1329906 · Cited by 641 · cited 1×
“Therefore, some suggest subclassifying stage C (54,60).”
Mazzaferro, V., Bhoori, S., Sposito, C., Bongini, M., Langer, M., Miceli, R., & Mariani, L. (2011) · Liver Transplantation · doi:10.1002/lt.22365 · Cited by 593 · cited 1×
“Due to the high rate of recurrence after transplant, the presence of tumor thrombus is considered an absolute contraindication to liver transplantation (79,80).”
BackgroundRisk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis
Amitrano, L., Anna Guardascione, M., Brancaccio, V., Margaglione, M., Manguso, F., Iannaccone, L., Grandone, E., & Balzano, A. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.01.001 · Cited by 582 · cited 1×
“Of note, upwards of 25% of all patients with cirrhosis have bland portal vein thrombus (50,51).”
BackgroundÖgren, M. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i13.2115 · Cited by 479
Bolondi, L., Burroughs, A. K., Dufour, J.-F., Galle, P. R., Mazzaferro, V., Piscaglia, F., Raoul, J., & Sangro, B. (2012) · BORIS (University Library Bern) · Cited by 320
Surgical Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
Shi, J., Lai, E. C. H., Li, N., Guo, W.-X., Xue, J., Lau, W. Y., Wu, M.-C., & Cheng, S.-Q. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0940-4 · Cited by 287 · cited 2×
“proposed a PVTT classification system based on the extent of tumor involvement (Table 4) (56).”
BackgroundBenign and malignant portal vein thrombosis: differentiation by CT characteristics.
Tublin, M. E., Dodd, G. D., & Baron, R. L. (1997) · American Journal of Roentgenology · doi:10.2214/ajr.168.3.9057522 · Cited by 269 · cited 4×
“The key feature for diagnosing portal vein tumor thrombus is the presence of enhancement or color Doppler flow within the thrombus (63,64).”
BackgroundInfluentialSorafenib in Advanced Hepatocellular Carcinoma
(2008) · New England Journal of Medicine · doi:10.1056/nejmc081780 · Cited by 250 · cited 1×
“Survival of those treated with Sorafenib is improved by only a modest 2–3 months (75,76).”
BackgroundYoon, S. M., Lim, Y.-S., Won, H. J., Kim, J. H., Kim, K. M., Lee, H. C., Chung, Y.-H., Lee, Y. S., Lee, S. G., Park, J.-H., et al. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.03.019 · Cited by 223 · cited 1×
“External beam radiation therapy in combination with intra-arterial 5-FU and interferon-alpha infusion has shown positive results (93,94).”
BackgroundSalem, R., Lewandowski, R., Roberts, C., Goin, J., Thurston, K., Abouljoud, M., & Courtney, A. (2004) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.0000123319.20705.92 · Cited by 211 · cited 1×
“Se lec t ive in terna l rad io-embol iza t ion (SIRT) using Yittrium-90 (Y-90) is considered by many to be the preferred treatment of patients with HCC and portal vein tumor invasion (88,89).”
MethodCatalano, O. A., Choy, G., Zhu, A., Hahn, P. F., & Sahani, D. V. (2010) · Radiology · doi:10.1148/radiol.09090304 · Cited by 210 · cited 2×
“com Diffusion imaging on MRI can be a useful adjunctive imaging finding (62).”
BackgroundHepatocellular carcinoma: A comprehensive review
Waller, L. P. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i26.2648 · Cited by 196 · cited 1×
“HCC is the 6th most common cancer and is the 3rd leading cause of cancer related deaths (46,47).”
BackgroundSurvival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients
Greten, T. F., Papendorf, F., Bleck, J. S., Kirchhoff, T., Wohlberedt, T., Kubicka, S., Klempnauer, J., Galanski, M., & Manns, M. P. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602590 · Cited by 194 · cited 1×
“This prognosis drops to 6 months if PVTT is present (52).”
BackgroundAdrenal cortical carcinoma a study of 77 cases
Nader, S., Hickey, R. C., Sellin, R. V., & Samaan, N. A. (1983) · Cancer · doi:10.1002/1097-0142(19830815)52:4<707::aid-cncr2820520424>3.0.co;2-n · Cited by 184
Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016
Chan, S. L., Chong, C. C., Chan, A. W., Poon, D. M., & Chok, K. S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i32.7289 · Cited by 183 · cited 1×
“HCC patients with any macroscopic vascular invasion are classified as Barcelona Clinic Liver Cancer (BCLC) stage C (advanced stage) (Table 5) (57-59).”
BackgroundSurgical treatment of hepatocellular carcinoma associated with hepatic vein tumor thrombosis
Kokudo, T., Hasegawa, K., Yamamoto, S., Shindoh, J., Takemura, N., Aoki, T., Sakamoto, Y., Makuuchi, M., Sugawara, Y., & Kokudo, N. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.04.032 · Cited by 167 · cited 3×
“The prognosis of HCC with tumor thrombus is a poor and depends on the extent of PVVT (48,49).”
BackgroundXue, T., Xie, X., Zhang, L., Yin, X. H., Zhang, B., & Ren, Z. (2013) · BMC Gastroenterology · doi:10.1186/1471-230x-13-60 · Cited by 160 · cited 1×
“However, in patients with non-occlusive thrombus, preserved liver function and small tumor burden, super-selective TACE can be safely and effectively performed with improvement in patient survival (83-85).”
BackgroundRossi, S. M., Ghittoni, G., Ravetta, V., Viera, F. T., de la Rosa, L. E. S., Serassi, M., Scabini, M., Vercelli, A., Tinelli, C., Bello, B. D., et al. (2008) · European Radiology · doi:10.1007/s00330-008-0931-z · Cited by 149 · cited 1×
“Contrast enhanced ultrasound is reported to be 100% sensitive and specific (65).”
BackgroundZielinski, H., Szmigielski, S., & Petrovich, Z. P. (2000) · American Journal of Clinical Oncology · doi:10.1097/00000421-200002000-00002 · Cited by 140 · cited 1×
“While it does decrease operative blood loss and shorten operative time, it has not been shown to improve overall survival (40-42).”
BackgroundChiche, L., Dousset, B. E., Kieffer, É., & Chapuis, Y. (2005) · Surgery · doi:10.1016/j.surg.2005.05.014 · Cited by 137 · cited 1×
“Similar to RCC with tumor thrombus, patients can present with a varicocele or lower extremity edema (97-99).”
BackgroundHaddad, A., Wood, C. G., Abel, E. J., Krabbe, L., Darwish, O. M., Thompson, R. H., Heckman, J. E., Merrill, M. M., Gayed, B. A., Sagalowsky, A. I., et al. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.03.111 · Cited by 115 · cited 1×
“Complete surgical resection of the parenchymal tumor and tumor thrombus results in a 5-year survival of greater than 50% (29-32).”
BackgroundWoodruff, D. Y., Veldhuizen, P. J. V., Muehlebach, G. F., Johnson, P., Williamson, T. L., & Holzbeierlein, J. M. (2011) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2011.03.006 · Cited by 114 · cited 2×
“If bland thrombus is present in addition to tumor thrombus, anticoagulation should be considered (36).”
BackgroundDall’Oglio, M. F., Ribeiro‐Filho, L. A., Antunes, A. A., Crippa, A., Nesrallah, L., Gonçalves, P. D., Leite, K. R. M., & Srougi, M. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.03.128 · Cited by 102 · cited 1×
“The presence of tumor thrombus changes staging, prognosis and surgical approach (4-8).”
BackgroundLeung, W.-T., Lau, W. Y., Ho, S. K. W., Chan, M., Leung, N. W. Y., Lin, J., Metreweli, C., Johnson, P. J., & LI, A. K. C. (1994) · PubMed · Cited by 97
Vascular Invasion in Hepatocellular Carcinoma: Prevalence, Determinants and Prognostic Impact
Lee, Y.-H., Hsu, C.-Y., Huang, Y., Hsia, C., Chiou, Y., Su, C., Lin, H.-C., & Huo, T. (2013) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3182a8a254 · Cited by 92 · cited 4×
“The prognosis of HCC with tumor thrombus is a poor and depends on the extent of PVVT (48,49).”
BackgroundInfluentialPrajapati, H. J., Dhanasekaran, R., El‐Rayes, B. F., Kauh, J. S. W., Maithel, S. K., Chen, Z., & Kim, H. S. (2013) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2012.11.026 · Cited by 76 · cited 1×
“However, in patients with non-occlusive thrombus, preserved liver function and small tumor burden, super-selective TACE can be safely and effectively performed with improvement in patient survival (83-85).”
BackgroundKatamura, Y., Aikata, H., Takaki, S., Azakami, T., Kawaoka, T., Waki, K., Hiramatsu, A., Kawakami, Y., Takahashi, S., Kenjo, M., et al. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-009-0033-y · Cited by 64
Vascular invasion by hepatocellular carcinoma
Choi, B. I. (1995) · Abdominal Imaging · doi:10.1007/bf00200417 · Cited by 56
Reig, M., Forner, A., & Bruix, J. (2012) · Wiley eBooks · doi:10.1002/9781444398441.ch11 · Cited by 44
Diffusion-Weighted MRI of Malignant versus Benign Portal Vein Thrombosis
Ahn, J.-H., Yu, J., Cho, E., Chung, J. B., Kim, J. H., & Kim, K. W. (2016) · Korean Journal of Radiology · doi:10.3348/kjr.2016.17.4.533 · Cited by 37 · cited 1×
“This is due to the high viscosity of thrombus as well as paramagnetic effects of intracellular deoxyhemoglobin and methemoglobin present in bland thrombus (67).”
BackgroundCharacterization of Portal Vein Thrombus With the Use of Contrast-Enhanced Sonography
Ueno, N., Kawamura, H., Takahashi, H., Fujisawa, N., Yoneda, M., Kirikoshi, H., Sakaguchi, T., Saito, S., & Togo, S. (2006) · Journal of Ultrasound in Medicine · doi:10.7863/jum.2006.25.9.1147 · Cited by 34 · cited 1×
“PVVT can be diagnosed and differentiated from bland thrombus by many different imaging modalities, including conventional angiography, color Doppler ultrasound, contrast enhanced ultrasound, contrast enhanced CT scan, MRI, and FDG PET imaging (61-64) (Table 3, Figures 2-4).”
BackgroundBerk, V., Ma, K., Tonyalı, Ö., Buyukberber, S., Balakan, O., Özkan, M., Demırcı, U., Ozturk, T., Bilici, A. E., Taştekin, D., et al. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.12.7367 · Cited by 31 · cited 1×
“There are many potential side effects of this drug; one characteristic side effect is hand-foot syndrome, which consists of redness, swelling, numbness and peeling of the palms of the hands and soles of the feet (74).”
BackgroundSurgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma
Liu, P., Hsia, C., Lee, Y.-H., Hsu, C., Huang, Y., Su, C., Lee, R., Lin, H., & Huo, T. (2015) · Journal of Surgical Oncology · doi:10.1002/jso.23854 · Cited by 28 · cited 1×
“Reflecting this practice, the Hong Kong Liver Staging does not consider hepatic vascular invasion to be a contraindication for surgical resection (78).”
Adrenocortical carcinoma presenting as varicocele and renal vein thrombosis: a case report
Cheungpasitporn, W., Horne, J. M., & Howarth, C. B. (2011) · Journal of Medical Case Reports · doi:10.1186/1752-1947-5-337 · Cited by 24 · cited 1×
“Similar to RCC with tumor thrombus, patients can present with a varicocele or lower extremity edema (97-99).”
BackgroundIslet cell tumor of the pancreas associated with tumor thrombus in the portal vein
Smith, T. M., Semelka, R. C., Noone, T. C., Balci, N. C., & Woosley, J. T. (1999) · Magnetic Resonance Imaging · doi:10.1016/s0730-725x(99)00039-9 · Cited by 22 · cited 1×
“This tumor thrombus can involve the splenic, the portal and/or the superior mesenteric veins (111-115).”
BackgroundAdrenocortical Carcinoma Invading the Inferior Vena Cava: Case Report And Literature Review
Mezhir, J. J., Song, J., Piano, G., Testa, G., Raman, J., Al‐Ahmadie, H. A., & Angelos, P. (2008) · Endocrine Practice · doi:10.4158/ep.14.6.721 · Cited by 15 · cited 5×
“It occurs in a wide variety of malignancies, most frequently in renal cell carcinoma (RCC), Wilms tumor, adrenal cortical carcinoma (ACC), and hepatocellular carcinoma (HCC).”
BackgroundInfluentialAdrenocortical carcinoma with tumor thrombus in the right hepatic vein
Reyes, M. A., Ciancio, G., Singal, R., & Manoharan, M. (2006) · International Journal of Urology · doi:10.1111/j.1442-2042.2006.01547.x · Cited by 9 · cited 1×
“Although there are some cases of long-term survival in cases of ACC with vascular invasion after complete resection, this is the exception rather than the rule (101-103).”
BackgroundAdrenocortical carcinoma with renal vein tumor thrombus extension.
Haghdani, S., Nayeri, R. K., Zargar, H. S., & Zargar, M. A. (2015) · Urology journal./Urology jornal. · Cited by 1
Metadata
- Authors
- Quencer, K. B., Friedman, T., Sheth, R., & Oklu, R.
- Venue
- Cardiovascular Diagnosis and Therapy
- Publisher
- AME Publishing Company
- Published
- 2017-12
- Volume
- 7
- Issue
- S3
- Pages
- S165-S177
- ISSN
- 2223-3652 (ISSN-L)
- 2223-3660
- OpenAlex
- W2766368269
- Cited by
- 222
- References
- 55
- FWCI
- 7.79
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.